In our new normal, driven by COVID-19, we appreciate that there is pressure on pharma companies to accelerate therapeutic drug development for patients with SARS-CoV-2, as well as a vaccine for its prevention. However, such pressure on medical resources has meant that, in recent months, clinical trials for other diseases have experienced widespread disruption. Keeping these trials on track is essential to bring much needed treatments to those that require them.
Read our latest whitepaper as our Subject Matter Experts outline how we can get these trials back on track, while adhering to evolving regulatory guidance and legislation from the relevant global authorities due to the pandemic.
Please complete the form to download our Whitepaper